BioFire FilmArray® Pneumonia Panel® Educational Handout

What is the BioFire FilmArray® Pneumonia Panel®?
A multiplex PCR test that detects certain organisms and resistance genes from respiratory samples. Results are available an hour after test initiated. This technology allows moving from empiric to targeted antimicrobial therapy earlier in treatment.

What does it identify?

Bacteria (semi-quantitative)	Viruses & Atypical Pathogens	Resistance Genes
Acinetobacter calcoaceticus-baumannii complex	*Legionella pneumophila*	Methicillin-resistance
Enterobacter cloacae	*Mycoplasma pneumoniae*	(mecA/mecC and MREJ)
Escherichia coli	*Chlamydia pneumonia*	
Haemophilus influenzae		ESBL
Klebsiella aerogenes	Influenza A	(CTX-M)
Klebsiella oxytoca	Influenza B	
Klebsiella pneumoniae group	Adenovirus	Carbapenemases
Moraxella catarrhalis	Coronavirus	(KPC, NDM, Oxa48-like, VIM, IMP)
Proteus spp.	Parainfluenza virus	
Pseudomonas aeruginosa	Respiratory Syncytial virus	
Serratia marcescens	Human Rhinovirus/Enterovirus	
Staphylococcus aureus	Human Metapneumovirus	
Streptococcus agalactiae		
Streptococcus pneumoniae		
Streptococcus pyogenes		

Note: The pneumonia panel is only capable of detecting organisms and resistance genes included in the list above. Almost all common HAP pathogens are present, but it won't detect all gram-negative pathogens (eg, *Stenotrophomonas, Morganella,* or *Citrobacter).*

How is it ordered/run?
The test is not ordered. It is run automatically on respiratory samples meeting the following criteria:

- Adult patients in an ICU at Atrium Health Wake Forest Baptist
- Quantitative culture obtained by BAL or TA

Note: The pneumonia panel will be performed on the first TA or BAL sample meeting testing criteria and will not be repeated on samples collected in the subsequent 72 hours. All samples will receive standard culture and susceptibility testing as well.

How will results be reported?
Results will appear as part of the respiratory culture report similar to how BCID2 PCR test results appear for blood cultures. The results for each target on the panel will appear a day or two prior to the standard culture results (see attached screen shot). When the organism identification and susceptibilities from the standard culturing processes are available, the culture report will be updated with this new information.

Note: When compared to cultures, the panel is very sensitive; it typically detects the organisms that grow on standard culture. However, because it can identify targets at low levels (including targets from dead organisms), it sometimes will detect organisms that do not grow on standard culture. Possible scenarios that explain positive and negative results:

- Panel reports that no organisms are detected can mean:
    - No organism is present (within detection limit of the test)
    - An organism not included in the panel is present (eg, *S. maltophilia)*
- Panel reports an organism (± a resistance gene). This can mean:
    - The organism detected will eventually grow on the culture

- The organism detected will not grow on culture; possible reasons include:
  - The panel identified target from dead organisms
  - The organism identified is difficult to grow on culture (eg, atypical bacteria)
  - The concentration of organism detected is too low to be significant
  - The patient is receiving current ABX therapy inhibiting cx growth

What decisions can be made based on the panel results?

As with all diagnostic tests, results from the respiratory panel need to be evaluated in view of the patient's unique scenario and clinical condition. Here are possible antimicrobial changes based on panel results that would be reasonable in most situations (assuming patient has pneumonia):

- If only gram-negative organism(s) identified: discontinue anti-MRSA agents
- If *S. aureus* susceptible to oxacillin (no *mecA/C* & MREJ) identified: change to targeted β-lactam therapy
- If only gram-positive organism(s) identified: de-escalate antipseudomonal agents
  - Consider discontinuing all gram-negative agents
- If both gram-positive and gram-negative organisms identified: tailor coverage as appropriate
- If organism identified is not covered by current therapy: modify therapy to treat pathogen(s)
- If no organisms identified, approach depends on clinical situation. Considerations:
  - Stop all antibiotics (if infection unlikely)
  - D/C anti-MRSA antibiotics (recommended for almost all situations)
  - Continue current antibiotics (if patient is severely ill and infection is suspected, but source of infection unclear)
  - Evaluate for another infectious source (if clinical condition indicates infection)

Examples of possible scenarios and potential therapy changes *(these examples assume patient has VAP & was started on empiric therapy of vancomycin/cefepime at time of culture; times after culture collection are hypothetical)*

Case	Time after culture obtained	Test result	Therapy change
1	8 hours	Panel: *Klebsiella oxytoca* detected	D/C vanc; continue cefepime
	24 h	GNRs growing from resp cxs	No change
	48 h	Final resp cx: *Klebsiella oxytoca*; susceptible to cefazolin	Change cefepime to cefazolin
2	8 h	Panel: *S. aureus* and MecA/C detected	Cont vanc; consider D/Cing cefepime or de-escalating to ceftriaxone (depending on pt condition)
	24 h	Only gram-positive cocci growing on resp cx	D/C gram-negative antibiotics if not done previously
	48 h	Final resp cx: MRSA	Cont vanc or change to PO linezolid
3	8 h	Panel: *E. coli* & CTX-M detected	D/C vanc; change cefepime to meropenem to cover ESBL
	24 h	GNRs growing from resp cxs	No change
	48 h	Final resp cx: ESBL-*E. coli* susceptible to cipro	Change meropenem to cipro as appropriate
4	8 h	Panel: MRSA & Pseudomonas detected	No change
	24 h	GPC growing on cx	No change
	48 h	Final resp cx: MRSA only	D/C cefepime (PsA likely non-significant as no growth on culture)

Whom do I contact for questions about the pneumonia panel?

Microbiology lab (6-2658) or CAUSE pager (6494)

Screen shot of pneumonia panel results



Pneumonia Panel

Collected 11/8/2021 16:19 Status: **Final result** Visible to patient: **No (inaccessible in myWakeHealth)**

Specimen Information: Bronchial Alveolar Lavage; Other

0 Result Notes

Component Ref Range & Units	11/8/21 1619
ACINTOBACTER CAL BAU COMPLEX Not Detected	**DETECTED** 1e6 copies/mL !
ENTEROBACTER CLOACAE COMPLEX Not Detected	Not Detected
ESCHERICHIA COLI Not Detected	Not Detected
HAEMOPHILUS INFLUENZAE Not Detected	**DETECTED** 1e5 copies/mL !
KLEBSIELLA AEROGENES Not Detected	Not Detected
KLEBSIELLA OXYTOCA Not Detected	Not Detected
KLEBSIELLA PNEUMONIAE GROUP Not Detected	Not Detected
MORAXELLA CATARRHALIS Not Detected	Not Detected
PROTEUS SP Not Detected	Not Detected
PSEUDOMONAS AERUGINOSA Not Detected	Not Detected
SERRATIA MARCESCENS Not Detected	Not Detected
STAPHYLOCOCCUS AUREUS Not Detected	Not Detected
STREPTOCOCCUS AGALACTIAE Not Detected	Not Detected
STREPTOCOCCUS PNEUMONIAE Not Detected	Not Detected
STREPTOCOCCUS PYOGENES Not Detected	Not Detected
CTX-M Not Detected, NOT_APPLICABLE	Not Detected

(Results for the remaining organisms and resistance genes on the panel would be similarly listed, followed by the narrative comment below. Results for "typical" bacteria include a semi-quantitative result when detected; atypical bacteria, viruses, and resistance genes only report if the target was detected or not.)



Narrative Performed by: WC Lab

CLINICAL INTERPRETATION: Detection of bacterial nucleic acid may be indicative of colonization or presence of normal respiratory flora and may not indicate the causative agent of pneumonia. Similarly detection of viral DNA may be indicative of persistence of DNA from a previous viral infection and may not indicate the causative agent of pneumonia. Clinical correlation is recommended. Semi-quantitative (copies/mL) results generated by the FilmArray Pneumonia Panel are not equivalent to CFU/mL and may not consistently correlate with the quantity of bacteria reported by the respiratory culture. Clinical correlation is advised to determine significance of semi-quantitative results (copies/mL) for clinical management.

METHODOLOGY: The FilmArray® Pneumonia Panel is a multiplexed nucleic acid test for the simultaneous detection and identification of multiple viral and bacterial pathogens, as well as select antimicrobial resistance genes.

COMMENT: The Pneumonia Panel test is performed by the laboratory on quantitative respiratory cultures obtained by BAL or tracheal aspiration from adult ICU patients at Atrium Health Wake Forest Baptist. Repeat testing will not be performed within 3 days of previous panel results.

The coronavirus detected by this assay will not detect Sars-CoV-2 (Covid-19).
This test has been approved by the U.S. Food and Drug Administration for bronchoalveolar lavage and tracheal aspirate specimens.

Specimen Collected: 11/11/21 13:56 Last Resulted: 11/11/21 13:58

Order Details | View Encounter | Lab and Collection Details | Routing | Result History